BG Medicine, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BGMD research report →
About the company
BG Medicine, Inc. is dedicated to the development and commercialization of diagnostic products aimed at guiding patient care for individuals in the United States afflicted with heart failure and related conditions. Its product portfolio includes the BGM Galectin-3 Test, an in vitro diagnostic solution that quantifies galectin-3 levels in blood serum or plasma using an enzyme-linked immunosorbent assay (ELISA) on a microtiter plate platform.
- CEO
- Stephen Hall
- IPO
- 2011
- Employees
- 5
- HQ
- Waltham, MA, US
Price Chart
- Market Cap
- $1.14K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.30
- Div Yield
- 0.00%
- Gross Margin
- 67.75%
- Op Margin
- -295.66%
- Net Margin
- -338.63%
- ROE
- 747.43%
- ROIC
- -485.83%
- Revenue
- $1.57M · -43.81%
- Net Income
- $-5,303,000 · 34.24%
- EPS
- $-0.55 · 44.44%
- Op Income
- $-4,630,000
- FCF YoY
- 55.10%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -44.60
- Avg Volume
- 1.46K
Get TickerSpark's AI analysis on BGMD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 4, 16 | LUBER JEFFREY R | other | 10,000 |
| Feb 4, 16 | LUBER JEFFREY R | other | 0 |
| Dec 9, 15 | AFEYAN NOUBAR | sell | 2,508 |
| Nov 18, 15 | PAPADOPOULOS STELIOS | other | 5,000 |
| Nov 18, 15 | AFEYAN NOUBAR | other | 5,000 |
| Jul 27, 15 | AFEYAN NOUBAR | other | 508 |
| Jul 27, 15 | AFEYAN NOUBAR | sell | 32 |
| Jul 27, 15 | AFEYAN NOUBAR | other | 254 |
| Jul 27, 15 | AFEYAN NOUBAR | sell | 16 |
| Jul 27, 15 | AFEYAN NOUBAR | other | 254 |
Our BGMD coverage
Recent articles, reports, and earnings notes.
No research on BGMD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BGMD report →Similar companies
Peers in the same neighborhood.